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Jun Nakamura2, Nobuyuki Yanagihara3 and Yoshiki Tokura1
Nitric oxide (NO) has several important roles in various physiological settings; one of the NO synthases,
inducible NO synthase (iNOS), is induced by external stimulation of the skin. A prototypic example of external
stimulation is hapten exposure, which induces the T-cell-mediated immune response known as contact
hypersensitivity (CHS). We herein report on cutaneous dendritic cell (DC) function in the presence of an iNOS-
specific inhibitor during the sensitization phase of CHS. First, we examined epidermal cell (EC) suspensions
using flow cytometry with an iNOS antibody and confirmed that iNOS was expressed in the cytoplasm of
Langerhans cells (LCs). We then studied the role of iNOS in CHS, and found that responses to DNFB were
enhanced by the addition of an iNOS inhibitor during sensitization. Similarly, the iNOS inhibitor augmented
FITC-induced migration of cutaneous DCs, including Langerinþ LCs and Langerin dermal DCs, to draining
lymph nodes. Finally, we showed that iNOS inhibitor enhanced LC survival in vitro. We concluded that NO
suppresses migration and survival of cutaneous DCs, resulting in a downmodulation of CHS.
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INTRODUCTION
Inducible nitric oxide (NO) synthase (iNOS) is one of the
three isoenzymes that generate NO from its precursor
L-arginine. In the skin, keratinocytes (Arany et al., 1996),
Langerhans cells (LCs) (Qureshi et al., 1996), dermal
fibroblasts (Wang et al., 1996), and melanocytes (Rocha
and Guillo, 2001) express iNOS upon stimulation with
inflammatory cytokines and/or lipopolysaccharide (LPS).
Although NO can be proinflammatory when produced in
large amounts, it may also regulate adaptive immune
responses (Kuchel et al., 2003). The best characterized
example is the induction of iNOS by LPS and IFN-g in
murine macrophages (Lu et al., 1996), LCs (Qureshi et al.,
1996), and keratinocytes (Yamaoka et al., 2000). Although
some information has thus been accumulated regarding the
in vitro effects of iNOS on skin immunocompetent cells, the
in vivo actions of iNOS remain unknown.
Murine contact hypersensitivity (CHS) is an antigen-
specific immune response consisting of the two phases,
namely, sensitization and elicitation. The constituents in-
volved in its pathogenesis are Th1/Tc1 cells serving as helper/
effector cells (Akiba et al., 2002); cutaneous dendritic cells
(DCs), including epidermal LCs and dermal DCs (dDCs), as
antigen-presenting cells (Kissenpfennig and Malissen, 2006);
and keratinocytes as a source of IL-1a, tumor necrosis factor-
a, and GM-CSF to the LCs (Sugita et al., 2007). iNOS is
induced in LCs and keratinocytes by contact allergens; this
supports the view that iNOS has a role in CHS (Morita et al.,
1996). It has previously been reported that an iNOS inhibitor
injected intradermally during the elicitation phase suppressed
CHS responses (Ross et al., 1998), but the specificity of this
iNOS inhibitor is not clear; furthermore, the role of iNOS in
the sensitization phase remains unknown.
In this study, we investigated the effects of an iNOS-
specific inhibitor in order to determine whether iNOS
functions as a positive or negative regulator in CHS. Our
results show that iNOS suppresses the CHS response by
downmodulating the migration and survival of DCs.
RESULTS
iNOS inhibitor enhances CHS response to DNFB
First, we tested the degree of CHS response in mice treated
with L-N6-iminoethyl-lysine (L-NIL), an iNOS inhibitor.
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The mice were sensitized and challenged with DNFB, and
their ear swelling responses were measured 24 hours after the
challenge. A significantly higher degree of ear swelling
response was observed in C57BL/6 (B6) mice treated
intraperitoneally with L-NIL throughout the sensitization
phase than in non-treated control mice (Figure 1a). Similar
results were obtained 48 hours after the challenge (data not
shown). In addition, histological analysis of the L-NIL-treated
mice showed a remarkable infiltration of lymphocytes into
the edematous dermis, which was not seen in untreated mice
(Figure 1b). To confirm that L-NIL was biologically active in
the skin when administered systemically, we measured the
NOx (NO2 þNO3 ) concentration of DNFB-sensitized skin.
NOx production induced by DNFB was inhibited by an
intraperitoneal injection of L-NIL (Supplementary Figure S1),
suggesting that L-NIL is biologically active in lesional skin
even when it is administered systemically.
iNOS expression in keratinocytes and LCs
Freshly isolated murine epidermal cells (ECs) were incubated
for 24 hours in a culture medium, and the LCs and
keratinocytes among them were analyzed for iNOS expres-
sion with flow cytometry. Both the keratinocytes and the LCs
bore iNOS in the cytoplasm (Figure 2a). iNOS expression was
greater in the mature LCs (major histocompatibility complex
(MHC) class II high expression) than in the immature LCs
(MHC class II intermediate expression). We carried out the
same analysis on ECs that had been cultured for 24 hours in
the presence of LPS, and found that LPS increased the number
of LCs that highly expressed iNOS (Figure 2b).
iNOS inhibitor increases cutaneous DC accumulation in
regional lymph nodes
To investigate the in vivo significance of iNOS for
cutaneous DCs, we performed an FITC-induced cutaneous
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Figure 1. Increased CHS response to DNFB caused by blockade of iNOS. (a) For CHS model, B6 mice were immunized by the application of 0.5% DNFB to
their shaved abdomens. They were challenged on both ears with 0.3% DNFB. iNOS inhibitor was applied through intraperitoneal injection (2.5mg in 0.5ml
PBS twice daily). Ear thickness swelling was measured 24 hours later. Data are expressed as the mean±SD of five mice. *Po0.05. (b) Non-sensitized ears,
challenged ears, and challenged ears from non-treated mice (inhibitor ) were stained with hematoxylin and eosin. Inset: close-up view of hematoxylin and
eosin staining of ears from mice treated with iNOS inhibitor, showing perivascular lymphocytic infiltration. Bar¼ 80 mm. Data are from three independent
experiments.
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DC migration assay. FITC applied to the skin is taken up by
cutaneous DCs, which subsequently migrate to the draining
lymph nodes as FITCþ MHC class IIþ cells. We intraper-
itoneally injected L-NIL, an iNOS inhibitor (2.5mg in 0.5ml
phosphate-buffered saline (PBS) twice daily for 4 consecutive
days) or the equivalent amount of PBS into mice; 24 hours
after the last injection, we applied FITC to the abdomen. We
then isolated axillary and inguinal draining lymph node cells
72 hours after FITC application and characterized the
FITCþMHC class IIþ cutaneous DCs therein by flow
cytometry. Staining for Langerin showed that two subsets of
the FITCþ MHC class IIþ cutaneous DCs, the dDCs and LCs,
were present in significantly greater numbers because
of treatment with iNOS inhibitor (Figure 3a and b).
Therefore, the blockade of iNOS promoted lymph node
accumulation of cutaneous DCs in response to skin exposure
to an antigen.
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Figure 2. Expression of iNOS by both keratinocytes and LCs. (a) EC
suspensions were analyzed for the expression of iNOS by means of flow
cytometry. For intracellular detection of iNOS, cell fixation–permeabilization
was performed before immunolabeling with anti-iNOS and anti-MHC class II
mAbs. LCs or keratinocytes were gated by MHC class II positivity. (b) EC
suspensions from naive mice were cultured with or without LPS (1 mgml1) for
24 hours. The cultured cells were subjected to a flow cytometric analysis,
which allowed us to measure the expression of iNOS. Data are from three
independent experiments.
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Figure 3. Augmented cutaneous DC accumulation in regional lymph nodes
by iNOS blockade. (a) Langerin expression and FITC fluorescence in cells
derived from regional lymph nodes were analyzed by means of flow
cytometry 72 hours after the application of 200 ml of 2% FITC. The percentage
of migrating LCs is indicated. (b) Migrating dDCs or LCs were counted
72hours after FITC painting. Columns show the mean±SD from at least four
mice per group. *Po0.05. (c) Expression of iNOS in migrating LCs and dDCs.
Draining lymph node cells were taken from mice painted with FITC on the
abdomen and stained with anti-MHC class II, Langerin, and iNOS mAbs.
Days 1, 2, and 3 indicate the number of days since FITC painting. Data are
expressed as mean fluorescence intensity (MFI) for iNOS. MFI was the value
of LCs or dDCs subtracted from that of the isotype-matched control. Columns
show the mean±SD. *Po0.01. Results are representative of three
independent experiments.
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iNOS expression in migrating LCs and dDCs
We examined iNOS expression in freshly isolated LCs and
dDCs, both of which are capable of migrating into the lymph
nodes on sensitization. The expression of iNOS in these cells
was examined with FITC and anti-Langerin mAb. FITC was
applied to the abdomen, and draining lymph node cells were
sampled 24, 48, and 72 hours later. These cells were then
labeled with anti-MHC class II mAb, anti-Langerin Ab, and
anti-iNOS Ab. Although LCs are positive for Langerin, most
dermal DCs are negative for Langerin (Nagao et al., 2009),
iNOS was present in both LCs and dDCs. The mean
fluorescence intensity for iNOS was as follows: LC,
11.9±4.1; dDC, 36.6±20.5 (mean±SD of three mice).
These data suggested that iNOS was weakly expressed only
in freshly isolated LCs and dDCs, in amounts too small to be
statistically significant. Nevertheless, we were able to observe
that the dDCs showed a higher mean fluorescence intensity
of iNOS expression than the LCs did (Figure 3c).
Chemotactic activity of LCs to CCL21
EC suspensions were incubated with LPS in a culture medium
for 9 hours and applied to transwells in the presence or
absence of L-NIL, an iNOS inhibitor. The migrating LCs in the
lower chamber were identified as MHC class IIþ cells.
CCL21 (CC chemokine ligand 21), a cytokine expressed in
secondary lymphoid organs that mediates the chemotaxis of
lymphocytes and DCs through its receptor, CCR7 (CC
chemokine receptor 7; Saeki et al., 1999), was then added
to the lower chamber. All LCs exhibited a strong chemotactic
response to this chemokine, but this response was signifi-
cantly increased by the iNOS inhibitor (Figure 4).
iNOS inhibitor caused no alteration of the expression of
co-stimulatory molecules or CCR7
The chemotaxis-promoting activity of the iNOS inhibitor,
described above, raised the possibility that the iNOS inhibitor
upregulates the expression of co-stimulatory molecules and
CCR7. To determine whether this is the case, freshly isolated
ECs were cultured for 24 hours in the presence or absence of
the iNOS inhibitor, and the expression levels of these
molecules were monitored by gating for MHC class IIþ
LCs. After 24 hours of culture, a single population of LCs
usually divides into two populations, with different expres-
sion levels of co-stimulatory molecules and CCR7 (Sugita
et al., 2007) (Figure 5a). The addition of the iNOS inhibitor
did not alter the expression of CD86, CD80, CD40, or CCR7
(Figure 5a and b). In chemotaxis, however, the expression of
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Figure 4. Chemotactic activity of epidermal LCs to CCL21. EC suspensions
were incubated with or without iNOS inhibitor plus LPS in culture medium
for 9 hours and applied to a transwell. CCL21 at 100 ngml1 was
administered to the lower chamber. Migrating epidermal LCs in the lower
chamber were identified as belonging to the MHC class IIþ subset. The
number of migrating LCs was calculated. Columns represent the mean±SD of
triplicated transwells, and data are from three independent experiments.
*Po0.01.
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Figure 5. No modulation of CD86, CD80, CD40, or CCR7 expression in LCs by iNOS inhibitor. (a and b) EC suspensions from naive mice were cultured for
24 hours with or without iNOS inhibitor. The cultured LCs were examined for their expression levels of CD86, CD80, CD40, and CCR7. Data are representative
of three independent experiments.
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CCR7 in DCs is not sufficient to guarantee its functionality
(Sanchez-Sanchez et al., 2006); therefore, it is possible that
iNOS alters certain downstream functions of LCs without
affecting CCR7 expression.
iNOS inhibitor reduces LPS-induced apoptosis of LC
We then evaluated the effect of endogenous iNOS activity on
the viability of LCs. EC suspensions from the earlobes of B6
mice were cultured for 9 hours with or without LPS in the
presence or absence of L-NIL, an iNOS inhibitor. LPS
stimulation reduced the number of LCs, but this reduction
was reversed by the addition of the iNOS inhibitor
(Figure 6a). It has been reported that epidermal LCs are
unable to proliferate in vitro when they are incubated as an
EC suspension (Schuler and Steinman, 1985), suggesting that
the observed effects of the iNOS inhibitor stem from a
survival change.
To examine whether the iNOS inhibitor promotes the
survival of LCs, cellular viability was assessed through flow
cytometry after Annexin V/propidium iodide staining and
9 hours of culture (Figure 6b). This flow cytometry experiment
used anti-MHC class II and anti-CD11c mAbs. The percen-
tage of Annexin V and propidium iodide double-positive cells
in samples that had been treated with 100mM iNOS inhibitor
and those that had not was as follows: 100mM, 1.6±0.4%; no
addition, 2.2±1.0% (mean±SD, n¼3). These results suggest
that the reduction of apoptotic cells that occurs through iNOS
inhibitor treatment is not due to the increment of necrotic
cells. We found that LPS-induced apoptosis of LCs was
reduced by the addition of the iNOS inhibitor (Figure 6c),
suggesting that the iNOS inhibitor promotes DC survival.
DISCUSSION
The results of this study on the effects of an iNOS inhibitor
include several major findings about the involvement of NO
in the sensitization phase of CHS. First, CHS as a model of
acquired skin immune response was enhanced by treatment
with the iNOS inhibitor. Second, the iNOS inhibitor
markedly increased the number of migrating cutaneous
DCs. Accordingly, the chemotactic response of LCs to
CCL21 was enhanced by in vitro incubation with the iNOS
inhibitor. Finally, the iNOS inhibitor was capable of reducing
LPS-induced apoptosis of LCs.
It has generally been believed that iNOS is involved in
CHS as a producer of NO and a trigger of inflammatory
responses (Cals-Grierson and Ormerod, 2004). It has been
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Figure 6. The effect of LPS on LC survival. (a) EC suspensions were cultured with or without LPS and iNOS inhibitor for 9–12 hours. iNOS inhibitor dose
dependently increased the number of LCs. Columns show the mean±SD. *Po0.05. Data are representative of three independent experiments. (b) Apoptosis
was determined using annexin V/propidium iodide double staining. (c) The percentage inhibition is calculated. Data represent the mean±SD. *Po0.05.
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reported that iNOS and NO were produced in human skin
subjected to positive patch tests to contact allergens (Cruz
et al., 2007; Ormerod et al., 1997) and to the irritant sodium
lauryl sulfate; nevertheless, it remains controversial whether
iNOS is inhibitory or augmentative in CHS (Ross and Reske-
Kunz, 2001). It has also been reported that an iNOS inhib-
itor exerted a suppressive effect on the CHS response to
2,4,6-trinitrochlorobenzene (TNCB) (Musoh et al., 1998),
although this effect was limited to the first few hours of the
response, and neither NO production, NO-expressing cells,
nor NOS isoenzymes were identified. Thus, the mode of
action of iNOS in CHS remains a matter of debate.
It is possible that iNOS first modulates keratinocytes so
that they produce cytokines, thereby subsequently modifying
LC function. Yet, we found that the production levels of GM-
CSF and tumor necrosis factor-a in the culture supernatant of
primary keratinocytes of B6 mice cultured for 72 hours were
not significantly affected by the presence of the iNOS
inhibitor (Supplementary Figure S2). With regard to the effect
of iNOS on T cells, we cultured immune CD4þ T cells for
72 hours with varying concentrations of the iNOS inhibitor in
the presence of anti-CD3 mAb and found that the iNOS
inhibitor was incapable of stimulating T cells per se
(Supplementary Figure S3).
LCs have traditionally been believed to have a role in the
induction of CHS, but three research groups have reported
three contradictory findings after applying haptens to
transgenic mice deficient in LCs: a diminished reaction
(Bennett et al., 2005), an enhanced reaction (Kaplan et al.,
2005), and an unchanged response (Kissenpfennig et al.,
2005). Moreover, recent findings suggest that dDCs has a
critical role in initiating CHS (Fukunaga et al., 2008). In our
study, dDCs augmented iNOS expression in response to
hapten application more than LCs did. Our findings suggest
that iNOS can suppress cutaneous DC migration and
survival. Given that, in CHS, dDCs and LCs have positive
and regulatory capacities, respectively, our findings on
cutaneous DCs seem to be consistent with the observation
that iNOS inhibitor induces an enhancement of CHS.
The findings of our study are clinically relevant in two
respects. First, iNOS and NO exert immunosuppressive
effects on cutaneous inflammation. In this context, the
in vivo immunosuppressive effect of NO has also been
shown in human studies (Kuchel et al., 2003). Second, iNOS
reduces cutaneous DC function and survival in the sensitiza-
tion phase of CHS. The observation that NO directly reduces
the number of LCs in the human epidermis supports our
conclusion (Mowbray et al., 2008).
MATERIALS AND METHODS
Animals and reagents
Female B6 mice were purchased from Japan SLC (Hamamatsu,
Japan). All experiments were conducted on 8-week-old mice. The
mice were maintained on a 12-hour light/dark cycle under a specific
pathogen-free condition. All protocols were approved by the
Institutional Animal Care and Use Committee of the University of
Occupational and Environmental Health. L-NIL (a highly selective
inhibitor of iNOS enzymatic activity) and LPS were obtained from
Sigma-Aldrich (St Louis, MO). CCL21 was purchased from R&D
Systems (Minneapolis, MN).
DNFB-induced CHS model
B6 mice were sensitized through the application of 25 ml of 0.5%
(v/v) DNFB in 4:1 acetone/olive oil to their shaved abdomens on
day 0. They were then challenged on both sides of each ear with
20 ml of 0.3% (v/v) DNFB. Ear thickness change was calculated as
follows: (ear thickness 24 or 48 hours after challenge)(ear thickness
before challenge). iNOS was inhibited with L-NIL as described
previously (Diefenbach et al., 1998). Briefly, L-NIL was applied
by intraperitoneal injection (2.5mg in 0.5ml PBS twice daily) for
6 consecutive days starting 1 day before sensitization. We chose
his protocol because treatment with L-NIL at this concentration
and frequency for 4-13 days is one of the most common methods
of blocking in vivo activity of iNOS (Diefenbach et al., 1998;
Stallmeyer et al., 1999).
EC preparation and culture
EC suspensions were prepared as described previously (Tokura et al.,
1994). Ears of naive mice were split along the plane of the cartilage,
which was then removed together with the subcutaneous tissue.
These specimens were incubated for 1 hour at 37 1C in a 0.2%
solution of trypsin in PBS. After incubation, the epidermis was
separated from the dermis and the separated epidermal sheets were
rubbed to disperse the ECs in PBS supplemented with 10% fetal calf
serum. The cells were filtered and washed twice in PBS. As a culture
medium, RPMI-1640 (Sigma-Aldrich) was supplemented with 10%
heat-inactivated fetal calf serum, 5 105 M 2-mercaptoethanol,
2mM L-glutamine, 25mM HEPES (4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid), 1mM nonessential amino acids, 1mM
sodium pyruvate, 100Uml1 penicillin, and 100 mgml1 strepto-
mycin.
Preparation of dermal cell suspensions
Dermal cells were obtained from normal murine skin from which the
epidermis had been removed. Samples were minced and incubated
for 2 hours at 37 1C in RPMI-1640 medium (Invitrogen, Carlsbad, CA)
supplemented with collagenase (2mgml1; Sigma-Aldrich), hyalur-
onidase (260Uml1; Sigma-Aldrich), DNase (0.1mgml1; ICN, Costa
Mesa, CA), and 10mM HEPES (Sigma-Aldrich). The obtained cells
were filtered through a 40-mm filter.
Flow cytometry
For flow cytometry, cells were plated at a density of 1 106 cells per
well in 96-well U-bottomed plates (Falcon, BD Biosciences, San
Jose, CA). Cells were then stained for 20minutes on ice with mAbs in
25 ml of PBS containing 2% fetal calf serum, 1mM EDTA, and 0.1%
NaN3, and washed twice with 200 ml of this buffer. Data were
collected on a FACSCanto system (BD Biosciences) and analyzed
with FlowJo software (TreeStar, San Carlos, CA). The mAbs used
were as follows: FITC-conjugated anti-CD86 and Annexin V mAbs,
PE-conjugated anti-CD80 and CD40 mAbs, PE-Cy5-conjugated anti-
MHC class II mAb, APC-conjugated anti-CD11c mAb (all from BD
Biosciences), and PE-Cy7-conjugated anti-CCR7 mAb (eBioscience,
San Diego, CA). For detection of Langerin and iNOS, anti-Langerin
Ab (eBioscience), PE-conjugated anti-iNOS Ab (Santa Cruz Biotech-
nology, Santa Cruz, CA), and PE-Cy5-conjugated streptavidin were
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used after fixation and permeabilization of cells using a Cytofix/
Cytoperm Kit (BD Biosciences).
Histology
At 48hours after the challenge with hapten, the ears of B6 mice were
excised and fixed in 10% formaldehyde. Sections of 5-mm thickness
were prepared and stained with hematoxylin and eosin.
FITC-induced cutaneous DC migration
The shaved abdomens of the mice were painted with 200 ml of 2%
FITC (Sigma-Aldrich) dissolved in a 1:1 (v/v) acetone/dibutyl
phthalate (Sigma-Aldrich) mixture, and the iNOS inhibitor was
applied through intraperitoneal injection (2.5mg in 0.5ml PBS)
twice daily for 4 days. Cutaneous DCs migrating into the draining
inguinal and axillary lymph nodes were then counted by means of
flow cytometry (Kabashima et al., 2007) using Flow-Count Fluoro-
spheres (Beckman Coulter, Fullerton, CA). The principle of Flow-
Count Fluorospheres is based on the precise mixing of microparticles
whose concentration and volume are known. Before flow cytometric
analysis, 10 ml of Flow-Count Fluorospheres were added to each
specimen. The percentages of fluorospheres and migrating DCs
within each node were then determined using the FACSCanto system
(BD Biosciences). To find the number of migrating DCs, the ratio of
DCs to fluorospheres was counted using the following formula,
based on Reimann et al. (2000), with some modifications: number of
migrating DCs¼ (percentage of migrating DCs/percentage of fluoro-
spheres) number of fluorospheres.
Chemotaxis assay
EC suspensions were incubated for 9 hours with or without the iNOS
inhibitor, and then tested for transmigration across uncoated 5-mm
transwell filters (Corning Costar, Corning, NY) to CCL21 or medium
in the lower chamber for 3 hours. Migrating cells were enumerated
by means of flow cytometry (Ngo et al., 1998). The medium used in
this assay was RPMI-1640 with 0.5% fatty acid-free bovine serum
albumin (Calbiochem, San Diego, CA).
Apoptosis analysis
The EC suspensions from B6 mice were stained with PE-Cy5-
conjugated anti-MHC class II mAb for 20minutes on ice, then
stained with FITC-conjugated Annexin V and propidium iodide (BD
Pharmingen, Franklin Lakes, NJ), according to the manufacturer’s
protocol. The number of LCs was assessed by means of flow
cytometry with anti-MHC class II and APC-conjugated anti-CD11c
mAbs. Apoptosis in LCs was analyzed using a FACSCanto system
with FlowJo software.
Statistical analysis
Data were analyzed using an unpaired two-tailed t-test. Po0.05 was
considered to be significant.
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